Profile data is unavailable for this security.
About the company
Valerio Therapeutics SA formerly Onxeo SA is a France-based clinical-stage biotechnology company. The company targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). It aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. It also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
- Revenue in EUR (TTM)1.89m
- Net income in EUR-19.66m
- Incorporated1997
- Employees38.00
- LocationValerio Therapeutics SA49 boulevard du General Martial ValinPARIS 75015FranceFRA
- Phone+33 145587600
- Fax+33 145580881
- Websitehttps://www.onxeo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valerio Therapeutics SA | 1.89m | -19.66m | 12.35m | 38.00 | -- | 3.06 | -- | 6.54 | -0.1233 | -0.1233 | 0.0119 | 0.0261 | 0.0515 | -- | 0.5121 | 99,421.05 | -53.59 | -34.19 | -76.22 | -40.59 | 74.75 | 84.11 | -1,040.66 | -586.99 | -- | -188.64 | 0.7662 | -- | 24.74 | -21.73 | -4.00 | -- | 32.39 | -- |
| SMAIO SA | 4.91m | -1.79m | 14.17m | 43.00 | -- | 1.76 | -- | 2.88 | -0.3383 | -0.3383 | 0.929 | 1.54 | 0.3738 | 0.3816 | 9.41 | 132,756.80 | -13.65 | -7.87 | -15.68 | -18.43 | 88.45 | 96.04 | -36.52 | -22.48 | 4.25 | -- | 0.236 | -- | 212.18 | 114.99 | -62.80 | -- | -- | -- |
| NicOx SA | -100.00bn | -100.00bn | 15.74m | 5.00 | -- | 0.7203 | -- | -- | -- | -- | -- | 0.3166 | -- | -- | -- | -- | -- | -22.59 | -- | -24.55 | -- | -- | -- | -337.85 | -- | -- | 0.5424 | -- | 26.59 | 11.38 | 33.26 | -- | -- | -- |
| Advicenne SA | 3.02m | -8.83m | 26.00m | 20.00 | -- | -- | -- | 8.61 | -0.7538 | -0.7538 | 0.2608 | -1.42 | 0.3234 | 3.85 | 1.87 | 150,950.00 | -94.59 | -57.86 | -- | -89.10 | -116.10 | -327.56 | -292.51 | -513.56 | 0.2611 | -22.23 | 156.51 | -- | 25.67 | 25.03 | 38.70 | -- | 55.28 | -- |
| Aelis Farma SA | 7.55m | -7.03m | 41.12m | 26.00 | -- | 4.00 | -- | 5.44 | -0.5319 | -0.5319 | 0.5717 | 0.75 | 0.2779 | -- | 1.56 | 290,461.50 | -25.85 | -24.53 | -40.55 | -40.55 | -- | -- | -93.03 | -109.62 | 2.97 | -- | 0.277 | -- | 137.70 | -- | 64.46 | -- | 37.35 | -- |
| AB Science SA | 1.08m | -6.04m | 51.53m | 45.00 | -- | -- | -- | 47.62 | -0.1204 | -0.1204 | 0.0213 | -0.4697 | 0.0385 | 0.6465 | 6.98 | 20,415.09 | -21.51 | -65.95 | -70.06 | -515.17 | 76.25 | 88.41 | -558.50 | -1,148.98 | 0.798 | -9.11 | -- | -- | 1.25 | -10.63 | 11.97 | -- | -6.55 | -- |
| Groupe Berkem SA | 52.43m | -1.42m | 54.37m | 200.00 | -- | -- | 15.99 | 1.04 | -0.0799 | -0.0799 | 2.95 | -- | -- | -- | -- | 262,130.00 | -- | -- | -- | -- | 56.41 | -- | -2.71 | -- | -- | 0.1565 | -- | -- | 0.733 | -- | 123.42 | -- | -- | -- |
| DBV Technologies SA | 13.12m | -83.97m | 60.02m | 106.00 | -- | 0.7963 | -- | 4.58 | -0.8733 | -0.8733 | 0.1365 | 0.781 | 0.0833 | -- | 0.7321 | 126,141.70 | -53.33 | -53.18 | -65.29 | -65.47 | -- | 93.62 | -640.08 | -1,145.92 | -- | -- | 0.083 | -- | 224.69 | -1.71 | 24.27 | -- | -34.47 | -- |
| Holder | Shares | % Held |
|---|---|---|
| OFI Invest Asset Management SAas of 29 Aug 2024 | 410.63k | 0.27% |
| Generali Asset Management SGR SpAas of 30 Dec 2022 | 0.00 | 0.00% |
